DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.
Storage Temp
Desiccated,Store at -80°C
Shipped In
Ice chest + Ice pads
Product Description
DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.
In Vitro
DAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression. DAMGO (1 μM) TFA effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na + current (TTX-R I Na ), i.e. PGE 2 (1 μM) can increase the TTX-R I Na peak by 103 % compared to 24.9 % with the addition of DAMGO. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DAMGO (i.v., 0.5-2 mg/kg) TFA can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
Associated Targets(Human)
CCKBRTclinGastrin/cholecystokinin type B receptor (2 Activities)
